home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9407a.zip
/
M9470142.TXT
< prev
next >
Wrap
Text File
|
1994-07-02
|
3KB
|
52 lines
Document 0142
DOCN M9470142
TI Valproic acid reduces the intracellular level of glutathione and
stimulates human immunodeficiency virus.
DT 9409
AU Simon G; Moog C; Obert G; Laboratoire commun Universite Louis
Pasteur/Synthelabo,; Strasbourg, France.
SO Chem Biol Interact. 1994 Jun;91(2-3):111-21. Unique Identifier :
AIDSLINE MED/94251837
AB Modifications of the glutathione (GSH) intracellular level have been
implicated in the regulation of human immunodeficiency virus (HIV)
transcription and expression. In regard to this hypothesis, we have
investigated the effects of valproic acid (VPA) on HIV replication.
Indeed, it has been recently reported that VPA inhibits the human red
blood cell glutathione reductase. In the supernatant of a CEM-SS
T-lymphocytic cell line infected with the LAI strain of HIV-1, we
observed an increase, in a dose-dependent fashion, of the reverse
transcriptase activity after treatment of cells with VPA. VPA also
induced HIV expression in the chronically infected monocytic U1 cell
line which constitutively expresses low levels of virus, enhanced the
HIV-long terminal repeat (LTR)-directed expression of beta-galactosidase
in transiently transfected Jurkat T-cells, and potentiated the PMA
effect on the LTR transactivation. GSH assays showed that VPA treatment
led to a decrease in the intracellular level of this thiol compound in
U937 (U1 parent-cell line) and in Jurkat T-cells. Work to understand the
molecular mechanism of VPA-induced HIV transcription and expression are
now in progress. VPA seems to be an adequate molecule to study the
implications of a GSH decrease in the stimulation of HIV replication.
However, a modification of the intracellular balance between reduced and
oxidized glutathione, rather than a simple reduction of the
intracellular glutathione level, could be of importance in the
regulation of HIV replication and we are now testing this hypothesis.
Finally, these findings already suggest that VPA, which is an
anticonvulsive drug frequently prescribed for the management of various
seizure disorders, should not be recommended for treatment of epilepsy
or other related illnesses in HIV-positive individuals.
DE beta-Galactosidase/GENETICS Cell Line Gene Expression Regulation,
Viral/DRUG EFFECTS Glutathione/*METABOLISM Granulocyte-Macrophage
Colony-Stimulating Factor/PHARMACOLOGY Human HIV Long Terminal
Repeat/DRUG EFFECTS HIV-1/*DRUG EFFECTS/GENETICS/PHYSIOLOGY
Interleukin-6/PHARMACOLOGY Monocytes/DRUG
EFFECTS/METABOLISM/*MICROBIOLOGY Oxidation-Reduction Reverse
Transcriptase/METABOLISM T-Lymphocytes/DRUG
EFFECTS/METABOLISM/*MICROBIOLOGY Tetradecanoylphorbol
Acetate/PHARMACOLOGY Transfection Tumor Cells, Cultured Tumor
Necrosis Factor/PHARMACOLOGY Valproic Acid/*PHARMACOLOGY Virus
Replication/DRUG EFFECTS JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).